Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mefatinib - Huadong Medicine

Next Previous
Drug Profile

Mefatinib - Huadong Medicine

Alternative Names: Mefatinib maleate - Huadong Medicine; MET-306; Mevanirtinib maleate - Huadong Medicine

Latest Information Update: 30 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Huadong Medicine
  • Class Amides; Antineoplastics; Chlorobenzenes; Dimethylamines; Fluorobenzenes; Maleates; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer

Most Recent Events

  • 21 Oct 2025 Registered for Non-small cell lung cancer (First-line therapy, Late-stage disease) in China (PO) - First global approval
  • 31 May 2024 Efficacy and adverse events data from the phase III trial in Non-small cell lung cancer presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 Nov 2022 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top